Key Takeaways Novo Nordisk and Eli Lilly cut obesity drug prices in China, with some Wegovy doses reduced by nearly 48%. The pricing move triggered share price declines, raising concerns over margins amid rising competition. Healthcare ETFs like XLV offer diversified exposure to obesity drugs while reducing single-stock risk. Recent reports suggesting that pharma giants Novo Nordisk (NVO) and Eli Lilly (LLY) have lowered prices for their blockbuster obesity drugs, Wegovy and Mounjaro, in China, have sent ri ...